Two 1-gallon pre-mixed containers of hemodialysis concentrates products CitraPure, RenalPure, or SteriLyte offer easier handling and streamlined workflow for patients, caregivers and healthcare providers

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has launched a Convenience Pack, which includes two 1-gallon pre-mixed containers of one of the Company's hemodialysis concentrate products CitraPure^®, RenalPure^®, or SteriLyte^®, offering a number of advantages for home patients and acute facilities.

"We are excited to offer home hemodialysis patients and acute care facilities a new, more ergonomic packaging option that is more accessible and easier to handle," said Tim Chole, Chief Commercial Officer at Rockwell Medical. "There is a patient-centric movement to drive dialysis treatments into the home to reduce the cost and complexity of dialysis treatments, all the while transforming the dialysis experience for patients. Rockwell is excited to become a critical player in the at-home market to support hemodialysis patients and their journey to take control over their time and treatments."

Rockwell Medical provides the hemodialysis community with high-quality products regulated by the U.S. Food and Drug Administration (FDA), reliable delivery services, and a robust Quality Management System. The Company is ISO 13485 Certified and adheres to current Good Manufacturing Practices (cGMP) and Association for Advancement of Medical Instrumentation (AAMI) standards. Rockwell manufactures a full suite of products including Citric Acid Concentrate Powders and Liquids; Acetic Acid Concentrate Powders and Liquids; Bicarbonate Concentrate Powders and Liquids; and Product Mixer, Cleaners and Accessories. For more information about Rockwell Medical's Convenience Pack, or to learn how you can include a Convenience Pack on your next order, please contact Rockwell Medical's Sales Team at www.rockwellmed.com/contact.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of hemodialysis concentrates. Certified as a Great Place to Work^® in 2023 and 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions^™. For more information, visit www.RockwellMed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will become the leading global supplier of hemodialysis concentrates. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807907576/en/